在上皮固体瘤中,BRAF III 类突变的治疗脆弱性和泛癌情景
Eylül Özgü1, Benjamin G Kaplan2, Smruthy Sivakumar2
1Medicana International Atasehir Hospital, Demiray Precision Oncology Center, Istanbul, Turkey.
BJC reports
|November 8, 2024
概括
第三类BRAF突变与不同的基因组资料有关,可能使瘤对抗EGFR治疗敏感. 对这些BRAF突变的查可能有利于具有有限选择的罕见癌症患者.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 癌症治疗方法 癌症治疗方法
背景情况:
- 与I和II类相比,III类BRAF突变代表了一个独特的子集,具有独特的激活机制和治疗漏洞.
- 关于泛癌基因组景观和III类BRAF突变的治疗影响的数据有限.
- 了解这些突变对于确定新的治疗标和预后因素至关重要.
研究的目的:
- 描述了瘤的泛癌基因组景观,这些瘤含有BRAF III类突变.
- 确定同时发生的变化及其对向疗法的影响,特别是抗EGFR药物.
- 探索BRAF III类突变作为抗EGFR治疗反应的预测生物标志物的潜力.
主要方法:
- 使用FoundationOne®或FoundationOne®CDx的376,302名患者的综合基因组分析.
- 用甲固定,嵌入的组织活检的分析.
- 介绍了两个患者病例,他们对抗EGFR治疗有显著的反应.
主要成果:
- BRAF III 类突变经常与 RAF1,NRAS 和 HRAS 变异同时发生,但很少与 KRAS 变异同时发生.
- 具有BRAF III类突变的瘤显著减少了预测抗EGFR剂耐药性的同时发生的变异.
- 报告的两例病例显示,抗EGFR疗法具有显著的临床益处.
结论:
- BRAF III 类突变定义了一种具有明显基因组异质性的新型瘤子集.
- 这些突变可能会使瘤对抗EGFR疗法的敏感,从而提供潜在的治疗途径.
- 对于治疗选择有限的罕见瘤,建议对BRAF III类突变进行查,因为它们可能受益于抗EGFR药物.
相关概念视频
Cancer-Critical Genes II: Tumor Suppressor Genes
7.3K
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
7.3K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K


